NASDAQ:TTNP Titan Pharmaceuticals - TTNP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.00 +0.01 (+1.01%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.96▼$1.0050-Day Range$0.77▼$1.0552-Week Range$0.35▼$1.59Volume37,443 shsAverage Volume39,752 shsMarket Capitalization$14.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Titan Pharmaceuticals (NASDAQ:TTNP) StockTitan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.Read More Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TTNP Stock News HeadlinesFebruary 1, 2023 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.comFebruary 1, 2023 | americanbankingnews.comTitan Pharmaceuticals (NASDAQ:TTNP) Earns Sell Rating from Analysts at StockNews.comFebruary 8, 2023 | Paradigm Press (Ad)Former CIA Advisor: Biden bombed Nord StreamIn the next 75 days, I predict Americans will face fuel shortages, widespread blackouts, empty grocery shelves, $1000 energy bills, drained retirement accounts… and a new crime wave. December 15, 2022 | finance.yahoo.comTitan Pharmaceuticals Provides Shareholder UpdateDecember 12, 2022 | nz.finance.yahoo.comTitan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.November 21, 2022 | bizjournals.comChapel Hill surgical tech company shapes plan to keep Nasdaq listingNovember 17, 2022 | finance.yahoo.comTitan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)November 4, 2022 | msn.comTitan, GAIL, TVS Motor, Britannia & Other Stocks to Release Q2 Results TodayFebruary 8, 2023 | Paradigm Press (Ad)Former CIA Advisor: Biden bombed Nord StreamIn the next 75 days, I predict Americans will face fuel shortages, widespread blackouts, empty grocery shelves, $1000 energy bills, drained retirement accounts… and a new crime wave. August 17, 2022 | benzinga.comTitan Pharmaceuticals Announces Board Expansion...August 16, 2022 | finance.yahoo.comTitan Pharmaceuticals Announces Board Expansion and Management ChangesJuly 11, 2022 | finance.yahoo.comActivist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of StockholdersJuly 9, 2022 | finance.yahoo.comHere's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn SituationJuly 6, 2022 | benzinga.comTitan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder StudyJuly 5, 2022 | nasdaq.comTitan Pharma Says FDA Clears IND Application For Nalmefene ImplantJuly 5, 2022 | finance.yahoo.comTitan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene ImplantJune 10, 2022 | finance.yahoo.comActivist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.April 25, 2022 | apnews.comActivist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.February 2, 2022 | finance.yahoo.comTitan Pharmaceuticals Raises $5.5M Via EquityFebruary 2, 2022 | marketwatch.comTitan Pharmaceuticals Shares Lower After Offering PricesFebruary 2, 2022 | seekingalpha.comTitan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offeringFebruary 2, 2022 | finance.yahoo.comTitan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-MarketDecember 21, 2021 | marketwatch.comTitan Pharmaceuticals Shares Up 17% On Company Exploring Strategic AlternativesDecember 21, 2021 | nasdaq.comTitan Pharma Exploring Strategic Alternatives; Stock Up 16% - Quick FactsDecember 21, 2021 | finance.yahoo.comTitan Pharmaceuticals to Explore Strategic AlternativesNovember 8, 2021 | finance.yahoo.comSustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021October 12, 2021 | finance.yahoo.comTitan Pharmaceuticals and MUSC FRD Enter Into Research and Option License AgreementSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TTNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TTNP Company Calendar Last Earnings3/30/2021Today2/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTNP CUSIPN/A CIK910267 Webwww.titanpharm.com Phone(650) 244-4990Fax650-244-4956Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,780,000.00 Net Margins-1,779.72% Pretax Margin-1,779.72% Return on Equity-183.12% Return on Assets-123.74% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.01 Sales & Book Value Annual Sales$1.53 million Price / Sales9.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book1.92Miscellaneous Outstanding Shares14,630,000Free Float14,234,000Market Cap$14.63 million OptionableOptionable Beta1.12 Key ExecutivesDavid Elliot LazarChairman, Chief Executive & Financial OfficerKatherine L. Beebe-DeVarneyPresident, Chief Operating Officer & DirectorBrian E. CrowleyVice President-FinanceStephen KilmerInvestor Relations ContactKey CompetitorsOrganovoNASDAQ:ONVOGenetic TechnologiesNASDAQ:GENEBrookline Capital AcquisitionNASDAQ:BCACInhibikase TherapeuticsNYSE:IKTIgnyte AcquisitionNASDAQ:IGNYView All CompetitorsInsiders & InstitutionsDavid E LazarBought 37,500 shares on 1/24/2023Total: $36,375.00 ($0.97/share)State Street CorpBought 38,287 shares on 11/15/2022Ownership: 0.262%Renaissance Technologies LLCSold 96,000 shares on 11/14/2022Ownership: 0.989%David E LazarBought 1,165,975 shares on 7/6/2022Total: $897,800.75 ($0.77/share)View All Insider TransactionsView All Institutional Transactions TTNP Stock - Frequently Asked Questions Should I buy or sell Titan Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTNP, but not buy additional shares or sell existing shares. View TTNP analyst ratings or view top-rated stocks. How have TTNP shares performed in 2023? Titan Pharmaceuticals' stock was trading at $0.7831 at the beginning of the year. Since then, TTNP stock has increased by 25.1% and is now trading at $0.98. View the best growth stocks for 2023 here. How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 1,779.72% and a negative trailing twelve-month return on equity of 183.12%. When did Titan Pharmaceuticals' stock split? Titan Pharmaceuticals's stock reverse split on the morning of Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Titan Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI). What is Titan Pharmaceuticals' stock symbol? Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP." Who are Titan Pharmaceuticals' major shareholders? Titan Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Titan Pharmaceuticals? Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Titan Pharmaceuticals' stock price today? One share of TTNP stock can currently be purchased for approximately $0.98. How much money does Titan Pharmaceuticals make? Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $14.34 million and generates $1.53 million in revenue each year. How can I contact Titan Pharmaceuticals? Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956. This page (NASDAQ:TTNP) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.